Free Trial
NASDAQ:LONA

Athira Pharma Q4 2025 Earnings Results & Report

Athira Pharma logo
$3.23 -0.24 (-6.92%)
As of 03:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Athira Pharma reported Q4 2025 earnings on March 26, 2026. The company reported EPS of -$18.90.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Athira Pharma EPS Results

Actual EPS
-$18.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Athira Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Athira Pharma Q4 2025 Earnings FAQ

Athira Pharma (NASDAQ:LONA) reported earnings of -$18.90 per share for Q4 2025. The report was announced on Thursday, March 26, 2026.

Athira Pharma Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Athira Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email.

About Athira Pharma

Athira Pharma (NASDAQ:LONA) is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair.

The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis. These were development-stage candidates, not approved medicines.

Athira was founded in 2011 and advanced its programs through clinical research. Fosgonimeton did not meet the primary endpoints in a Phase 3 Alzheimer’s disease study, and the company subsequently reassessed its development plans.

View Athira Pharma Profile